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Abstract
Background: Misoprostol vaginal insert for induction of labor has been recently reported to be superior to
dinoprostone vaginal insert in a phase III trial, but has never been compared to vaginal misoprostol in another
galenic form. The aim of this study was to compare misoprostol vaginal insert (MVI) with misoprostol vaginal
tablets (MVT) for induction of labor in term pregnancies.
Methods: In this retrospective cohort study we compared 200 consecutive women induced with 200-μg
misoprostol 24-h vaginal insert (Misodel®) with a historical control of 200 women induced with Misoprostol 25-μg
vaginal tablets (Cytotec®) every 4-6 h. Main outcomes variables included induction-to-delivery interval, vaginal
delivery within 24-h, incidence of tachysystole, mode of delivery, and neonatal outcome. A subanalysis in the MVI
group was performed in order to identify predictive factors for tachysistole and vaginal delivery within 24 h.
Results: The time from induction to vaginal delivery was 1048 ± 814 min in the MVI group and 1510 ± 1043 min in
the MVT group (p < 0.001). Vaginal delivery within 24-h occurred in 127 (63.5%) patients of the MVI group and in
110 (55%) patients of the MVT group (p < 0.001). Tachysystole was more common in the MVI group (36% vs. 18%;
p < 0.001). However, no significant predictors of uterine tachysystole in MVI group have been identified in crude
and fully adjusted logistic regression models. Bishop score was the only predictor for vaginal delivery within 24 h
(p < 0.001) in MVI group. Caesarean delivery rate (27% vs. 20%) and vaginal-operative deliveries (15.5% vs. 15.5%)
did not differ significantly between the two groups. Neonatal outcomes were similar in both groups.
Conclusions: MVI achieves a more vaginal delivery rate within 24 h and Tachysystole events compared to MVT.
However, no differences in caesarean section, operative vaginal delivery, and neonatal outcomes are reported. No
predictors of tachysistole after MVI administration have been identified. Bishop score and parity are the only
predictors of vaginal delivery within 24 h after MVI administration.
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Background
Labour induction is a commonly performed procedure
in obstetrics with an increasing incidence of approxi-
mately 25% [1–3]. In the latest decades, several pharma-
cological and mechanical methods of labour induction
have been developed. Success of labour induction is
linked to the Bishop score. An unfavourable cervix char-
acterized by low cervical Bishop score decreases the suc-
cess of labour induction and therefore is associated with
a higher incidence of caesarean sections (CS) [4–7]. In
this context, the use of prostaglandins has proven to be
more effective for cervical ripening in women with low
Bishop score as compared to other commonly used
methods (oxytocin, Foley catheter, amniotomy), but is
associated with an increased rate of uterine tachysystole,
hyperstimulation syndrome, and uterine rupture [8, 9].
Misoprostol is a prostaglandin E1 analogue currently
marketed as oral tablets for the prophylaxis and treat-
ment of peptic ulcer disease. Although the obstetrical
use of Misoprostol is off-label in most countries, an ex-
tensive literature have proven its safety, efficacy, and
dose-response effect in labour induction at term preg-
nancies [8]. Its pharmacological characteristics com-
pared to prostaglandins E2, along with its easiness of
storage led to the widespread use in obstetrics [10, 11].
Moreover, the World Health Organization entered
Misoprostol in the list of the essential drugs for ob-
stetrical use and medical organisations such as the
International Federation of Gynaecology and Obstet-
rics and the American College of Obstetrician and
Gynaecologists recommended their use in pregnant
women [2, 12–15].
In 2014 misoprostol was registered in Europe in form
of a single controlled-release vaginal insert containing
200 μg, and approved for labour induction beyond 37 0/
7 weeks’ gestation [16]. A large phase III registration trial
reported a favourable outcome with a similar rate in va-
ginal deliveries and CS in comparison with dinoprostone
vaginal insert [17]. Misoprostol vaginal insert (MVI) use
resulted in a reduced induction-to-delivery interval,
reduced time to active labour, and decreased need for
additional oxytocin. At the same time, uterine tachysys-
tole requiring intervention was increased (13.3% vs. 4%)
[17], whereas no difference in neonatal outcome could
be observed. So far, no data are available about the com-
parison between MVI and MVT. The aim of the follow-
ing study was therefore to compare MVI to MVT in
terms of vaginal delivery within 24 h and maternal/fetal
outcomes. Secondary outcome was the identification of
predictors of vaginal birth within 24 h. Furthermore, this
study aims to identify the predictive factors for the
occurrence of uterine tachysystole associated with MVI
use, since it is the only significant adverse outcome
reported in the MVI group.
Methods
Between January 2012 and July 2016, a retrospective
cohort study was conducted at the Department of Obte-
trics and Gynaecology, University Hospital Bern – Insel-
spital (Switzerland). We included all consecutive women
who had a labour induction > 36 0/7 weeks’ gestation.
Before May 2014, MVT was routinely used off-label for
labour induction in this patient population. In May
2014, MVT was replaced with the novel, approved MVI.
The analysis periods were set as follows: January 2012 to
30 April 2014 for the MVT cohort and 1 May 2014 to
31 July 2016 for the MVI cohort. Data were obtained
from the patients’ electronic medical records. Each
patient signed an informed consent regarding data col-
lection for scientific purpose. Exclusion criteria consisted
in foetal malpresentation, previous CS or uterine scar-
ring (e.g., previous caesarean section), < 36 + 0 weeks of
gestation, premature rupture of the membranes less than
24-h before starting the induction, severe preeclampsia,
body mass index (BMI) > 50, signs of maternal infections
in peripheral blood samples, abnormal foetal heart rate
tracings or signs of active labour at admission, and twin
pregnancy. Patients received MVI (Misodel®, Ferring Inc.
, Saint-Prex, Switzerland) containing 200 μg misoprostol
in a slow-release vaginal insert as a single application,
left in place for a maximum of 24 h, or MVT with re-
petitive dosing every 4 h as indicated. MVT were pre-
pared in the hospital’s pharmacy by crushing Cytotec®
(Pfizer Inc., New York, US) tablets containing 200 μg
misoprostol and manufacturing custom-made vaginal
tablets each containing 25 μg misoprostol. In each
group, preparations were placed in the posterior vaginal
fornix. Criteria for removing MVI and ceasing MVT
administration were the onset of three or more contrac-
tions within 10 min, lasting for 45 s or longer, resulting
in cervical change or leading to a cervical dilatation of
4 cm or more with any frequency of contractions, or
after completion of the 24-h dosage period. If spontan-
eous rupture of the membranes occurred, antibiotic
prophylaxis was started after 24 h or immediately if a
vaginal group B streptococcal smear test was positive. In
both groups, an interval of at least 30 min was set be-
tween the removal of the vaginal insert or the last ad-
ministration of vaginal tablet and the start of
intravenous oxytocin administration.
Baseline demographic data and patients’ characteristics
were prospectively collected including maternal age,
BMI, parity, contractions and membrane rupture status,
gestational age, Bishop score (evaluated at the time of
labour induction), and ethnicity. Each patient underwent
at least 30 min of cardiotocography assessment to record
the foetal status and confirm that there was no uterine
pattern of active labour before the induction. Time and
mode of delivery (vaginal, CS, operative vaginal) were
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recorded. Primary outcome was the rate of vaginal deliv-
ery within 24 h. Secondary outcomes were the
induction-to-vaginal delivery interval (IDI), rate of cae-
sarean section and operative vaginal delivery, the pro-
portion of women requiring predelivery oxytocin, and
the rate of uterine tachysystole. Further outcomes in-
cluded the rate of peridural anaesthesia or other pain re-
lievers, uterine hyperstimulation syndrome, postpartaum
haemorrhage, uterine rupture, and length of hospital
stay (days). Uterine tachysystole was defined by any oc-
currence of five or more contractions within 10 min, av-
eraged over three consecutive 10-min periods [18].
Uterine hyperstimulation syndrome was defined as uter-
ine tachysytole with concurrent foetal heart rate deceler-
ations or bradycardia [18]. Neonatal outcome included
the rates of 5-min Apgar score < 7, umbilical artery/ven-
ous pH, and umbilical artery base excess − 12 mmol/L,
presence of meconium and transfer to neonatal intensive
care unit. Ethical approval for the study was obtained by
the local institutional review board (Ethics Committee of
the Canton of Bern, Switzerland).
Statistical analysis
The patients characteristics and the delivery outcomes
of the two groups were compared using Student’s t-test
for continuous variables and chi-square test for dichot-
omous variables. Continuous values were expressed as
mean ± standard deviation. Unpaired continuous data
were analyzed using the Mann-Whitney test. Propor-
tions were compared by the Fisher’s exact test. A p value
< 0.05 was considered to be statistically significant. P
values with more then 3 decimals were reported as >/<
0.001. Age of the mother, BMI, ethnicity, parity, gesta-
tional age at delivery, Bishop score, indication for labour
induction, and fetal weight were evaluated as predictors
for vaginal delivery within 24 h and for tachysistole, in
crude and fully logistic regression models (OR 95%).
Data analysis was performed with GraphPad Prism ver-
sion 5 for Mac (GraphPad Software, San Diego CA).
Results
During the study interval a total of 400 women were in-
cluded, 200 consecutive women induced with MVI and
200 consecutive women induced with MVT. The clinical
characteristics of the study population are summarized
in Table 1. Both groups were homogenous with similar
baseline characteristics, except for BMI. Vaginal deliv-
ery within 24 h occurred in 127 (63.5%) patients of
the MVI group and 110 (55%) patients of the MVT
group (p < 0.001). Induction-to-vaginal delivery inter-
val was 1048 ± 814 min and 1510 ± 1043 min in the
MVI and MVT group, respectively (p < 0.001) (Fig. 1).
Uterine tachysystole was more frequent in the MVI
group (36% n = 72 vs. 18% n = 36; p = 0.002). No
significant differences were detected in the rate of
epidural anaesthesia or other pain reliever use. CS
rate (27% n = 54 vs. 20% n = 41, p = 0.58) and
vaginal-operative deliveries (15.5% n = 31 vs. 15.5%
n = 31, p = 0.77) were not significantly different be-
tween the groups. Postpartum haemorrhage occur-
rence was also similar in both groups (12.9% n = 25
vs. 9% n = 18, p = 0.33). No uterine rupture occurred.
Neonatal outcomes (Apgar score, cord blood pH,
transfer to neonatal intensive care unit) were not
significantly different in both groups. Women in the
MVI group had a significantly shorter length of
hospital stay calculated in hours as compared with
women in the MVT group (MVI 97.63 ± 32. vs MVT
Table 1 Patients characteristics
MVI
n 200
MVT
n 200
p-Value
Median Age (range) 32 (28-35) 32(28-36) > 0.05
Mean Parity (±SD) 0.5 ± 0.7 0.6 ± 1 > 0.05
Median BMI (range) 22.8 (20.7-25.3) 24.2 (21.6-27.6) < 0.001
Mean week of gestational
age at delivery(±SD)
40 ± 1 39 ± 1 > 0.05
Ethnicity (%)
Europe 149 (74.5) 153 (76.5) > 0.05
Africa 27 (13.5) 25 (12.5) > 0.05
America 5 (2.5) 4 (2.0) > 0.05
Asia 17 (8.5) 18 (9.0) > 0.05
Missing 2 (1.0) 0 (0.0) > 0.05
Premature rupture of
membrane (%)
19 (9.5) 12 (6) > 0.05
Median Bishop’s score (range) 2 (1-3) 2 (1-3) 1
Student’s t-test was used for Age, parity, BMI, week of gestational age, and
Bishop score; chi-square test was used for Etnicity and Premature rupture
of Membrane
Abbreviations: BMI Body mass index, MVI Misoprostol vaginal insert, MVT
Misoprostol vaginal tablets
Fig. 1 Vaginal delivery within 24-h after induction of labour with
MVI compared to MVT. Abbreviations: MVI = Misoprostol vaginal
insert, MVT =Misoprostol vaginal tablets
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118.5 ± 123; p < 0.001). Further deliveries outcomes
are summarized in Table 2.
Since uterine tachysistole was significantly higher in
MVI group, the predictors of uterine tachysystole among
patients induced with MVI were interrogated and no
significant association were found with the demographic
and clinical parameters and therefore predictive power is
lacking (Table 3). Bishop’s score and parity were the
strongest predictors of delivery within 24 h after adjust-
ing for confounders in the same group (OR 0.90, CI 95%
0.85-0.96 p < 0.001) (Table 4).
Discussion
MVT was compared to other methods such as oxytocin,
Dinoprostone and placebo in several clinical randomized
trials in terms of efficacy (vaginal delivery within 24 h)
and safety (perinatal or maternal outcomes) (8). Recently,
MVI was compared to Dinoprostone vaginal insert, a
prostaglandin E2 analog in a phase III trial reporting sig-
nificantly reduced times to delivery (efficacy) and no evi-
dence of differences in maternal or neonatal safety
outcomes (safety) (17). Since this study, three studies have
compared the vaginal insert to other induction methods
in terms of delivery outcomes [19–21]. However, none of
these studies have compared MVI to MVT.
Our study shows for the first time that labour induc-
tion with MVI has a significant higher rate of vaginal
delivery within 24 h, and a shorter hospital stay com-
pared to the labour induction with MVT. The two
groups of patients were homogeneous for clinical and
demographic characteristics, except for the BMI (p <
0.001). However, mean BMI values were lower than
25.00 Kg/m2 both in MVI and MVT groups. Since
the overweight women with a BMI up to 25.00 kg/
Table 2 MVI vs MVT deliveries outcomes
MVI
n = 200
MVT
n = 200
P value
Vaginal delivery within
24 h n°(%)
127 (63.5%) 110 (55%) < 0.001
Induction to vaginal delivery
interval minutes mean (±SD)
1048 ± 814 1510 ± 1043 < 0.001
Predelivery oxytocin n°(%) 6 (3) 11 (5.5) > 0.05
Peridural anesthesia
n°(%)
79 (39.5) 65 (32) > 0.05
Pain reliviers (excl. PDA)
n°(%)
132 (66) 143 (71.5) > 0.05
Uterine Hyperstimulation
n°(%)
13 (6.5) 13 (6.5) > 0.05
Tachysistole
n°(%)
72 (36) 36 (18) 0.002
Apgar < 7 n (%) 8 (4) 2 (1) > 0.05
pH art < 7.15 n° (%) 36/149 (24) 25/161 (15) > 0.05
Umbelical artery base excess
mean ± SD
−3.7 ± 3 −4.1 ± 3 > 0.05
Neonatal birth weight
mean ± SD
3428 ± 429 3389 ± 471 > 0.05
Meconium n°(%) 29 (14) 29 (14) > 0.05
NICU n°(%) 14 (7) 20 (10) > 0.05
Abbreviations: NICU Neonatal intensive care unit, MVI Misoprostol vaginal
insert, MVT Misoprostol vaginal tablets
Table 3 Predictors of uterine tachysystole in MVI group
Crude OR
(95% CI)
p-Values Adjusted OR
(95% CI)
p-Values
Age of mother 0.71 (0.42-1.20) 0.19 0.69 (0.38-1.26) 0.23
BMI 0.99 (0.93-1.06) 0.81 0.99 (0.92-1.06) 0.73
Ethnicity 0.82 0.87
Europe 1.00 (reference) 1.00 (reference)
Africa 1.49 (0.65-3.42) 1.45 (0.56-3.72)
America 1.24 (0.20-7.68) 1.35 (0.17-8.84)
Asia 1.02 (0.36-2.91) 1.03 (0.30-3.23)
Parity 1.05 (0.72-1.54) 0.80 1.06 (0.68-1.65) 0.79
Gestations age 1.05 (0.84-1.31) 0.65 1.05 (0.77-1.44) 0.75
Bishop’s score 1.01 (0.83-1.23) 0.92 1.02 (0.82-1.27) 0.86
over due date 1.00 (reference) 1.00 (reference)
gestational
diabetes mellitus
1.33 (0.57-3.12) 1.65 (0.54- 5.06)
other 0.88 (0.44-1.73) 1.24 (0.49 -3.16)
Fetus weight 1.23 (0.63-2.42) 0.54 1.23 (0.56-2.74) 0.60
Odds ratios (OR) and 95% CI for the occurrence of uterine tachysystole.
Predictors from crude and fully adjusted logistic regression models. Age of the
mother is taken in decades, and fetus weight was entered in kg
Table 4 Predictors of vaginal deliveries within 24 h in MVI
group
Crude OR
(95% CI)
p-Values Adjusted OR
(95% CI)
p-Values
Age of mother 0.97(0.83-1.12) 0.64 1.02 (0.87-1.20) 0.81
BMI 1.02 (1-1.04) 0.41 1.01 (0.99-1.03) 0.25
Ethnicity 0.72 0.51
Europe 1.00 (reference) 1.00 (reference)
Africa 0.9 (0.7-1.15) 0.96 (0.73-1.23)
America 1.06 (0.61-1.82) 1.12 (0.66-1.88)
Asia 1.10 (0.81-1.50) 1.23 (0.90-1.69)
Parity 0.81 (0.73-0.90) < 0.001 0.84 (0.74-0.95) 0.004
Gestations age 0.95 (0.89-1.01) 0.12 1.02 (0.94-1.11) 0.66
Bishop’s score 0.89 (0.84-0.94) < 0.001 0.90 (0.85-0.96) < 0.001
over due date 1.00 (reference) 1.00 (reference)
gestational
diabetes mellitus
1.37 (1.06-1.75) 1.43 (1.05-1.94) 0.55
other 1.22 (1-1.48) 1.14 (0.92 -1.41) 061
Fetus weight 0.91(0.75-1.11) 0.34 1.23 (0.56-2.74) 0.22
Odds ratios (OR) and 95% CI for the occurrence of vaginal delivery within 24 h.
Predictors from crude and fully adjusted logistic regression models. Age of the
mother is taken in decades, and fetus weight was entered in kg
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m2are at increased risk of pregnancy complications at
birth [22], we can speculatively justify the similar number
of operative deliveries and CSs, and neonatal outcomes in
the two groups despite the difference in BMI.
Furthermore, in MVI an increased incidence of uterine
tachysystole was reported. However, this finding was not
accompanied by an higher rate of operative deliveries, CS;
similarly, neonatal outcomes do not differ among the
groups. Interesting, we found that uterine tachysystole
cannot be predicted by demographic or clinical factors.
In our study, adverse events such as CS, postpartum
haemorrhage, meconium-stained amniotic fluid, Apgar
score below 7, fetal acidosis (defined by arterial pH < 7.
15), and neonatal complications were similar in both
groups. In line with previous studies, we detected a rela-
tively high incidence of uterine tachysystole after Miso-
prostol use [8, 23, 24]. For example, Jozwiak et al.
reported a 61% reduction of uterine hyperstimulation in
the Foley catheter group compared to the use of 25 μg
MVT and Hofmeyr et al. reported a lower incidence of
tachysystole with similar results using vaginal / intracer-
vical dinoprostone [8, 23]. Efficacy of misoprostol seems
to be correlated with the dosage and therefore several
studies focused on determining the optimal dosing regi-
men. In our study the dosages used in the MVT group
was previously reported as the most effective for vaginal
delivery success and is associated with the lowest rates
of tachysystole [8]. Similarly, the efficacy and safety of
MVI was evaluated with different dosages. For example,
Wing et al. compared three different doses of MVI and
determined that 200 μg was the most effective for the
onset of active labour within 24-h but with the disadvan-
tage of an increased rate of tachysystole (41.2%) com-
pared to MVI 150 μg (25.6%) and MVI 100 μg (19.5%)
[25]. In our study, the incidence of tachysytole was sig-
nificantly higher than in the MVT group (36% vs. 18%).
However, this higher incidence did not result in adverse
maternal and/or neonatal outcomes. Further, the multi-
variate analysis displayed no maternal or fetal predictive
factors for tachysytole. We hypothesize that the main
reason for the higher incidence of uterine tachysytole
are the pharmacokinetic properties of MVI such as the
relatively long elimination half-time after removal of
40 min [16]. Thus, timely removal of the vaginal insert
may reduce the incidence of tachysytole. Whether the
inclusion of currently excluded patients with certain
characteristics such as multiparty, low BMI, or rupture
of membranes is warranted, needs to be evaluated in fur-
ther prospective studies.
A general goal of clinical management during pregnancy
is to avoid adverse maternal and fetal outcomes while
avoiding unnecessary CS. For this reason, ACOG recom-
mend in uneventful pregnancies inductions of labour at
41 0/7 weeks of gestations to reduce the number of
elective CS and to improve perinatal outcomes [15]. How-
ever, several studies have shown an increased rate of failed
induction and CS if women are induced with an unfavour-
able cervix [4–7]. In this context prostaglandins are effect-
ive agents for cervical ripening [8]. In our study, we
observed that MVI did not reduce the CS rate but the time
to delivery and therefore a significant reduction of hospital
stay. Theoretically, the shorter hospital stay may be related
to the higher rate of vaginal delivery within 24 h, however
it is just a speculative assumption. If so, it might be benefi-
cial for patients, particularly for those needing a rapid deliv-
ery such as late onset preeclampsia [26]. Although MVI
(Misodel, 74.37 USD) might be more expensive compared
to the MVT (Cytotec tablet, 0.26 USD), the reduced hos-
pital stay outweighs this disadvantage. Furthermore, the liti-
gation risks inherent to the use of misoprostol off-label can
be avoided using the approved MVI preparation. A further
important aspect is the women’s preference regarding com-
fort and pain during induction of labour. As reported by
Impey et al., women’s expectation is to have a safe and fast
labour with little pain [27]. Another study showed that 40%
of women who experienced a labour induction expressed
the desire to minimize the time duration of labour induc-
tion in case of the necessity of labour induction in the fol-
lowing pregnancy [28]. In this regard, MVI has the
potential to increase patient satisfaction by decreasing the
time to delivery interval. Limit of this study is its retrospect-
ive nature, and prospective future studies are needed to
confirm our proof of concept.
Conclusions
MVI is able to induce higher rate of vaginal delivery
within 24 h compared to MVT. A shorter hospital stay
was also reported in the MVI group. The higher rate of
tachysystole after MVI induction may represent the price
to be paid for a quicklier time interval from induction to
delivery. However, although more tachysystole events are
reported after MVI induction, no differences in maternal
and neonatal outcomes as well as in operative deliveries
and CS are observed when comparing to MVT. Further-
more, no predictors of vaginal delivery within 24 h are
identified in the MVI group, except for Bishop score and
parity. It means that probably we need further prospective
studies in order to identify which modifiable predictors
can be used in the future to better select the patients to a
more appropriate labour induction program.
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